Md Anderson

HealthPosted by

Dr. Stephen Hahn, 24th US FDA Commissioner And Former Chief Medical Executive At MD Anderson, Joins Flagship Pioneering As Chief Medical Officer Of Flagship's Preemptive Medicine And Health Security Initiative

CAMBRIDGE, Mass., June 14, 2021 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that Stephen Hahn, M.D. will help lead its Preemptive Medicine and Health Security initiative as Chief Medical Officer, and join Flagship's Senior Leadership Team, effective June 16, 2021. Dr. Hahn served as the U.S. Food and Drug Administration Commissioner from 2019-2021. Prior to joining the FDA, he was the Chief Medical Executive, The University of Texas MD Anderson Cancer Center.

Give blood: MD Anderson faces critical shortage of blood

HOUSTON – Save a life, and give blood. MD Anderson Blood Bank announced Thursday there is a shortage of blood for cancer patients. Due to the holiday weekend and an ongoing nationwide shortage, the blood bank said it’s a challenging time to collect blood products. They are asking the public to give blood.
Picture for Give blood: MD Anderson faces critical shortage of blood
Houston, TXPosted by

MD Anderson to test personalized mRNA vaccines as cancer treatment

HOUSTON — More than 100 million Americans have gotten two doses of Pfizer or Moderna’s COVID-19 vaccines. Both are mRNA vaccines, which use cutting edge technology never authorized for use before. Dr. Van Morris with MD Anderson says the technology was developed years before the pandemic. It was originally intended...
Harris County,

MD Anderson and Refuge Biotechnologies collaborate to advance next-generation cell therapies for treatment of solid tumors

Collaboration supports co-development of RB-340 CAR T cell therapy, application of Refuge’s synthetic biology platform to MD Anderson TIL programs. The University of Texas MD Anderson Cancer Center and Refuge Biotechnologies, Inc. today announced a strategic collaboration to advance new cell therapies for potential treatment of solid tumors. The agreement pairs Refuge’s innovative technologies with the experience and industrial capabilities of MD Anderson’s Biologics Development platform, within the Therapeutics Discovery division.

MD Anderson, Broad Institute launch rare cancer research platform

The University of Texas MD Anderson Cancer Center in Houston and Cambridge, Mass.-based Broad Institute of MIT and Harvard are aiming to accelerate novel therapeutics for rare cancers by generating a catalog of more than 100 rare cancer models, the organizations announced May 11. As part of the effort, researchers...

MD Anderson and Broad Institute launch new translational research platform focused on rare cancers

Newswise — HOUSTON and BOSTON ― The University of Texas MD Anderson Cancer Center and the Broad Institute of MIT and Harvard today announced the launch of a new translational research platform to study rare cancers and develop a first-of-its-kind resource for the scientific community. The joint initiative will create a catalog of rare cancer models and provide a data resource to accelerate the identification of therapeutics to treat patients diagnosed with rare tumor types.

MD Anderson and Boehringer Ingelheim expand collaboration to accelerate development of KRAS and TRAILR2 compounds in lung cancer

Agreement builds on successful preclinical studies in gastrointestinal cancers through the joint Virtual Research and Development Center. The University of Texas MD Anderson Cancer Center and Boehringer Ingelheim today announced the extension and expansion of their joint Virtual Research and Development Center (VRDC) to explore new molecules from Boehringer Ingelheim’s KRAS (Kirsten rat sarcoma) and TRAILR2 (TNF-related apoptosis-inducing ligand receptor 2) portfolios for the potential treatment of lung cancer, particularly non-small cell lung cancer.

MD Anderson and TriSalus Life Sciences announce strategic research collaboration to evaluate treatment of solid tumors

Newswise — HOUSTON, DENVER and CHICAGO ― The University of Texas MD Anderson Cancer Center and TriSalus Life Sciences today announced a strategic research collaboration to evaluate the treatment of tumors of the pancreas and liver by integrating interventional delivery of SD-101, an investigational toll-like receptor 9 (TLR9) agonist, in combination with checkpoint inhibition immunotherapy.